- Home
- AGEN vs LRFC Comparison
AGEN vs LRFC Comparison
Compare AGEN & LRFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- LRFC
- Stock Information
- Founded
- AGEN 1994
- LRFC 2013
- Country
- AGEN United States
- LRFC United States
- Employees
- AGEN N/A
- LRFC N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- LRFC Finance: Consumer Services
- Sector
- AGEN Health Care
- LRFC Finance
- Exchange
- AGEN Nasdaq
- LRFC Nasdaq
- Market Cap
- AGEN 52.6M
- LRFC 47.6M
- IPO Year
- AGEN 2000
- LRFC 2013
- Fundamental
- Price
- AGEN $3.47
- LRFC $17.90
- Analyst Decision
- AGEN Buy
- LRFC
- Analyst Count
- AGEN 4
- LRFC 0
- Target Price
- AGEN $8.33
- LRFC N/A
- AVG Volume (30 Days)
- AGEN 1.0M
- LRFC 13.2K
- Earning Date
- AGEN 05-12-2025
- LRFC 05-08-2025
- Dividend Yield
- AGEN N/A
- LRFC 8.04%
- EPS Growth
- AGEN N/A
- LRFC N/A
- EPS
- AGEN N/A
- LRFC N/A
- Revenue
- AGEN $99,524,000.00
- LRFC $20,544,000.00
- Revenue This Year
- AGEN $14.67
- LRFC N/A
- Revenue Next Year
- AGEN N/A
- LRFC N/A
- P/E Ratio
- AGEN N/A
- LRFC N/A
- Revenue Growth
- AGEN N/A
- LRFC 3.11
- 52 Week Low
- AGEN $1.38
- LRFC $17.30
- 52 Week High
- AGEN $19.69
- LRFC $26.00
- Technical
- Relative Strength Index (RSI)
- AGEN 67.96
- LRFC 33.56
- Support Level
- AGEN $2.83
- LRFC $17.46
- Resistance Level
- AGEN $4.06
- LRFC $18.01
- Average True Range (ATR)
- AGEN 0.34
- LRFC 0.31
- MACD
- AGEN 0.04
- LRFC 0.16
- Stochastic Oscillator
- AGEN 58.74
- LRFC 57.05
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About LRFC Logan Ridge Finance Corporation
Logan Ridge Finance Corp an externally managed non-diversified closed-end management investment company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company offers customized financing to business owners, management teams, and financial sponsors for change of ownership transactions, recapitalizations, strategic acquisitions, business expansion, and other growth initiatives.